No Deficit To Shire’s Top Line In ADHD
This article was originally published in The Pink Sheet Daily
Executive Summary
New product sales drive firm’s revenue growth, including an impressive market grab by attention deficit/hyperactivity disorder product Vyvanse.
You may also be interested in...
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD
British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.
Daytrana Manufacturing Woes Continue With FDA Warning Letter
Jan. 9 warning letter cites manufacturing deficiencies related to the transdermal ADHD patch.